Related Experiment Video

Updated: Dec 25, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

[The Therapeutic Potency of Natural Products against Heart Failure]

Yoichi Sunagawa1,2,3

  • 1Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|April 3, 2020
PubMed

Insights

Curcumin, a natural compound, shows therapeutic potential for preventing heart failure. This review covers basic research and clinical trials exploring curcumin

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Nutritional Science

Background:

  • Chronic heart failure (CHF) is a significant global health issue, often resulting from conditions like hypertension and myocardial infarction.
  • The incidence of heart failure has risen, particularly in developed nations, necessitating novel therapeutic strategies.
  • Natural products are increasingly recognized for their potential in preventing disease progression, including heart failure.

Purpose of the Study:

  • To review the translational research on curcumin for preventing and treating heart failure.
  • To establish the pharmacological therapeutic value of curcumin in the context of heart failure.
  • To explore the clinical applications of curcumin as a therapeutic agent for heart failure.

Main Methods:

  • Review of basic scientific studies on curcumin's effects on heart failure.
  • Analysis of clinical trials investigating curcumin's therapeutic potential in heart failure patients.
  • Evaluation of preclinical data and human studies to assess curcumin's efficacy and safety.

Main Results:

  • Curcumin, a polyphenol from Curcuma longa, demonstrated therapeutic potency against heart failure in previous animal studies.
  • Basic research indicates curcumin's beneficial effects on cardiovascular health and heart failure pathways.
  • Clinical trials are exploring curcumin's efficacy in preventing and managing heart failure.

Conclusions:

  • Curcumin holds significant promise as a therapeutic agent for preventing and managing chronic heart failure.
  • Further clinical investigation is warranted to fully establish curcumin's role in heart failure treatment.
  • Translational research supports the potential use of curcumin as a nutritional supplement for cardiovascular health.

Keywords:
bioavailabilitycardiovascular diseasecurcuminheart failure

More Related Videos

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.4K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.9K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
816
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
161
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
732
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
677
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
186